vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $11.5M, roughly 1.7× TRANSACT TECHNOLOGIES INC). On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs 11.9%). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-97.3M). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 3.5%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
AGIO vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $11.5M |
| Net Profit | $-108.0M | — |
| Gross Margin | 90.6% | 47.6% |
| Operating Margin | -608.9% | -10.1% |
| Net Margin | -541.1% | — |
| Revenue YoY | 86.1% | 11.9% |
| Net Profit YoY | -11.9% | — |
| EPS (diluted) | $-1.86 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $11.5M | ||
| Q3 25 | $12.9M | $13.2M | ||
| Q2 25 | $12.5M | $13.8M | ||
| Q1 25 | $8.7M | $13.1M | ||
| Q4 24 | $10.7M | $10.2M | ||
| Q3 24 | $9.0M | $10.9M | ||
| Q2 24 | $8.6M | $11.6M | ||
| Q1 24 | $8.2M | $10.7M |
| Q4 25 | $-108.0M | — | ||
| Q3 25 | $-103.4M | $15.0K | ||
| Q2 25 | $-112.0M | $-143.0K | ||
| Q1 25 | $-89.3M | $19.0K | ||
| Q4 24 | $-96.5M | — | ||
| Q3 24 | $947.9M | $-551.0K | ||
| Q2 24 | $-96.1M | $-319.0K | ||
| Q1 24 | $-81.5M | $-1.0M |
| Q4 25 | 90.6% | 47.6% | ||
| Q3 25 | 87.0% | 49.8% | ||
| Q2 25 | 86.3% | 48.2% | ||
| Q1 25 | 87.6% | 48.7% | ||
| Q4 24 | 88.3% | 44.2% | ||
| Q3 24 | 91.3% | 48.1% | ||
| Q2 24 | 82.6% | 52.7% | ||
| Q1 24 | 92.3% | 52.6% |
| Q4 25 | -608.9% | -10.1% | ||
| Q3 25 | -907.4% | 0.1% | ||
| Q2 25 | -1020.1% | -1.9% | ||
| Q1 25 | -1222.0% | -0.1% | ||
| Q4 24 | -1165.3% | -10.3% | ||
| Q3 24 | -1146.9% | -7.7% | ||
| Q2 24 | -1228.3% | -3.8% | ||
| Q1 24 | -1124.3% | -12.2% |
| Q4 25 | -541.1% | — | ||
| Q3 25 | -803.1% | 0.1% | ||
| Q2 25 | -899.4% | -1.0% | ||
| Q1 25 | -1023.3% | 0.1% | ||
| Q4 24 | -899.6% | — | ||
| Q3 24 | 10574.7% | -5.1% | ||
| Q2 24 | -1115.7% | -2.8% | ||
| Q1 24 | -995.8% | -9.7% |
| Q4 25 | $-1.86 | $-0.11 | ||
| Q3 25 | $-1.78 | $0.00 | ||
| Q2 25 | $-1.93 | $-0.01 | ||
| Q1 25 | $-1.55 | $0.00 | ||
| Q4 24 | $-1.44 | $-0.80 | ||
| Q3 24 | $16.22 | $-0.06 | ||
| Q2 24 | $-1.69 | $-0.03 | ||
| Q1 24 | $-1.45 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $31.1M |
| Total Assets | $1.3B | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $20.4M | ||
| Q3 25 | $92.7M | $20.0M | ||
| Q2 25 | $80.9M | $17.7M | ||
| Q1 25 | $79.0M | $14.2M | ||
| Q4 24 | $76.2M | $14.4M | ||
| Q3 24 | $253.7M | $11.3M | ||
| Q2 24 | $84.5M | $11.1M | ||
| Q1 24 | $118.8M | $10.6M |
| Q4 25 | $1.2B | $31.1M | ||
| Q3 25 | $1.3B | $31.8M | ||
| Q2 25 | $1.4B | $31.3M | ||
| Q1 25 | $1.5B | $30.9M | ||
| Q4 24 | $1.5B | $30.6M | ||
| Q3 24 | $1.6B | $38.4M | ||
| Q2 24 | $660.5M | $38.5M | ||
| Q1 24 | $743.9M | $38.6M |
| Q4 25 | $1.3B | $44.8M | ||
| Q3 25 | $1.4B | $45.0M | ||
| Q2 25 | $1.5B | $44.5M | ||
| Q1 25 | $1.6B | $44.2M | ||
| Q4 24 | $1.7B | $44.0M | ||
| Q3 24 | $1.8B | $50.5M | ||
| Q2 24 | $773.1M | $50.4M | ||
| Q1 24 | $849.7M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $609.0K |
| Free Cash FlowOCF − Capex | $-97.3M | $589.0K |
| FCF MarginFCF / Revenue | -487.5% | 5.1% |
| Capex IntensityCapex / Revenue | 5.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $609.0K | ||
| Q3 25 | $-88.2M | $3.6M | ||
| Q2 25 | $-77.1M | $3.6M | ||
| Q1 25 | $-111.5M | $-161.0K | ||
| Q4 24 | $-133.2M | $2.4M | ||
| Q3 24 | $-84.2M | $327.0K | ||
| Q2 24 | $-72.6M | $636.0K | ||
| Q1 24 | $-99.9M | $-1.5M |
| Q4 25 | $-97.3M | $589.0K | ||
| Q3 25 | $-89.7M | $3.6M | ||
| Q2 25 | $-78.0M | $3.6M | ||
| Q1 25 | $-112.3M | $-171.0K | ||
| Q4 24 | $-134.1M | $2.4M | ||
| Q3 24 | $-84.6M | $259.0K | ||
| Q2 24 | $-72.7M | $499.0K | ||
| Q1 24 | $-100.0M | $-1.6M |
| Q4 25 | -487.5% | 5.1% | ||
| Q3 25 | -696.5% | 27.1% | ||
| Q2 25 | -626.2% | 25.9% | ||
| Q1 25 | -1286.4% | -1.3% | ||
| Q4 24 | -1250.1% | 23.2% | ||
| Q3 24 | -944.2% | 2.4% | ||
| Q2 24 | -844.4% | 4.3% | ||
| Q1 24 | -1221.2% | -14.9% |
| Q4 25 | 5.6% | 0.2% | ||
| Q3 25 | 12.1% | 0.5% | ||
| Q2 25 | 7.0% | 0.1% | ||
| Q1 25 | 8.8% | 0.1% | ||
| Q4 24 | 9.0% | 0.1% | ||
| Q3 24 | 4.7% | 0.6% | ||
| Q2 24 | 1.8% | 1.2% | ||
| Q1 24 | 1.7% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
